Evidence mapPaperPMID 37584728Full record

ArticleDiabetologia2023

Glucose-lowering effects of a synbiotic combination containing Pediococcus acidilactici in C. elegans and mice.

Deyan Yavorov-Dayliev, Fermín I Milagro, Josune Ayo, María Oneca, Ignacio Goyache, Miguel López-Yoldi, Paula Aranaz

Open access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Low-Molecular-Weight Bovine Collagen Peptides Reduce Fat Accumulation inInternational journal of molecular sciences · 2025
    Article
  9. Review
  10. Article
  11. Postbiotic pA1cInternational journal of molecular sciences · 2025
    Article
  12. Article
  13. Heat-InactivatedInternational journal of molecular sciences · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Probiotics in reducing obesity by reconfiguring the gut microbiota.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Review
  18. International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Deyan Yavorov-DaylievGenbioma Aplicaciones SL, Navarra, Spain.
Fermín I MilagroFac Pharm & Nutr, Dept Nutr Food Sci & Physiol, University of Navarra, Pamplona, Spain. fmilagro@unav.es.ORCID 0000-0002-3228-9916
Josune AyoGenbioma Aplicaciones SL, Navarra, Spain.
María OnecaGenbioma Aplicaciones SL, Navarra, Spain.
Ignacio GoyacheFac Pharm & Nutr, Dept Nutr Food Sci & Physiol, University of Navarra, Pamplona, Spain.
Miguel López-YoldiFac Pharm & Nutr, Dept Nutr Food Sci & Physiol, University of Navarra, Pamplona, Spain.
Paula AranazCenter for Nutrition Research, University of Navarra, Pamplona, Spain.ORCID 0000-0002-1282-0079
Navarrabiomed · ESUniversidad de Navarra · ESInstituto de Salud Carlos III · ESNavarre Institute of Health Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisModulation of gut microbiota has emerged as a promising strategy to treat or prevent the development of different metabolic diseases, including type 2 diabetes and obesity. Previous data from our group suggest that the strain Pediococcus acidilactici CECT9879 (pA1c) could be an effective probiotic for regulating glucose metabolism. Hence, the objectives of this study were to verify the effectiveness of pA1c on glycaemic regulation in diet-induced obese mice and to evaluate whether the combination of pA1c with other normoglycaemic ingredients, such as chromium picolinate (PC) and oat β-glucans (BGC), could increase the efficacy of this probiotic on the regulation of glucose and lipid metabolism.

methodsCaenorhabditis elegans was used as a screening model to describe the potential synbiotic activities, together with the underlying mechanisms of action. In addition, 4-week-old male C57BL/6J mice were fed with a high-fat/high-sucrose diet (HFS) for 6 weeks to induce hyperglycaemia and obesity. Mice were then divided into eight groups (n=12 mice/group) according to dietary supplementation: control-diet group; HFS group; pA1c group (10

resultsSupplementation with the synbiotic (pA1c+PC+BGC) counteracted the effect of the high glucose by modulating the insulin-IGF-1 signalling pathway in C. elegans, through the reversal of the glucose nuclear localisation of daf-16. In diet-induced obese mice, all groups supplemented with the probiotic significantly ameliorated glucose tolerance after an IPGTT, demonstrating the glycaemia-regulating effect of pA1c. Further, mice supplemented with pA1c+PC+BGC exhibited lower fasting blood glucose, a reduced proportion of visceral adiposity and a higher proportion of muscle tissue, together with an improvement in the brown adipose tissue in comparison with the HFS group. Besides, the effect of the HFS diet on steatosis and liver damage was normalised by the synbiotic. Gene expression analyses demonstrated that the synbiotic activity was mediated not only by modulation of the insulin-IGF-1 signalling pathway, through the overexpression of GLUT-1 and GLUT-4 mediators, but also by a decreased expression of proinflammatory cytokines such as monocyte chemotactic protein-1. 16S metagenomics demonstrated that the synbiotic combinations allowed an increase in the concentration of P. acidilactici, together with improvements in the intestinal microbiota such as a reduction in Prevotella and an increase in Akkermansia muciniphila. CONCLUSIONS/

interpretationOur data suggest that the combination of pA1c with PC and BGC could be a potential synbiotic for blood glucose regulation and may help to fight insulin resistance, diabetes and obesity.

Indexed as

Diabetes Mellitus, Type 2Pediococcus acidilacticiSynbioticsAnimalsBlood GlucoseCaenorhabditis elegansDiet, High-FatGlucoseInsulinInsulin-Like Growth Factor IMaleMiceMice, Inbred C57BLMice, ObeseObesityRNA, Ribosomal, 16SBlood GlucoseGlucoseInsulinInsulin-Like Growth Factor IRNA, Ribosomal, 16SDiabetesMicrobiotaObesityProbioticsSynbioticThe metabolic syndrome

Identifiers

PMID37584728
PMCPMC10542285
OpenAlexW4385850659

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.